Orphan Drugs Would Get User Fee Waivers With Greater Ease Under House Bill
Executive Summary
Provisions in the House version of the FDA user fee bill would raise the cut-off for an orphan drug to qualify for a user fee waiver from firms with less than $10 million in annual revenue to firms with less then $100 million
You may also be interested in...
Orphan Drugs May Grow More Common As Medicine Becomes More Personal
As drug research increasingly focuses on identifying patients who will most benefit from a given therapy, more drugs will qualify for orphan status and companies will be able to take advantage of the economic incentives to develop those drugs
Orphan Drugs May Grow More Common As Medicine Becomes More Personal
As drug research increasingly focuses on identifying patients who will most benefit from a given therapy, more drugs will qualify for orphan status and companies will be able to take advantage of the economic incentives to develop those drugs
Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008
For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: